The trial starts on Monday 11 July and will continue for three months to allow the College to determine levels of demand for such a service and, therefore, whether it should be made permanent.
Eleanor Ferguson, RCVS Acting Registrar, said: "This was a potential service identified in our Strategic Plan as a way of allowing veterinary professionals to have informal, confidential, discussions with members of the Professional Conduct Department about potential fitness to practise issues, short of formally raising a concern.
"Although any discussions via the new reporting line or email address will be confidential, if a veterinary surgeon or a veterinary nurse subsequently wishes to raise a formal concern about another veterinary professional, then they generally will need to identify both themselves and the individual in order to take it through our investigation process.
"We have developed a bespoke concerns form for members of the professions who do want to raise concerns about other professionals."
Veterinary surgeons and veterinary nurses who wish to contact a member of the RCVS Professional Conduct Department in confidence can do so by calling 07599 958 294 between 9am and 5pm, or by emailing reporting@rcvs.org.uk.
The bespoke concerns from for members of the profession can be downloaded from www.rcvs.org.uk/concerns.
Now, when you advertise a job on VetSurgeon.org, the system can send a message to all your employees (and any contacts in the profession) asking them to pass it on if they know anyone suitable, and to share the advertisement on their other social networks, such as Facebook.
As a further option, practices can also now offer a cash reward for a successful introduction leading to the post being filled. In that case, the message sent to employees and contacts lets them know that there’s a reward for their help.
VetSurgeon.org Editor Arlo Guthrie said: "Since we relaunched VetSurgeon Jobs, I’ve noticed a correlation between the number of times that job advertisements are shared by email or on Facebook, and the success that practices have in filling the vacancy.
"Of course, there is nothing to stop you emailing staff and contacts yourself, or offering a reward. But I suspect many don’t, and my hope is that this new feature will really help focus the mind, streamline the process and ultimately help you find the person who'll fit in with your team."
"Share & Reward is another feature exclusively available on VetSurgeon Jobs, alongside the VetSurgeon Locums Map and Find Our Jobs on VetSurgeon (a badge for your website that links to just your jobs).
"There's more on the way!"
The service will be available to veterinary practices that use more than £250/€300 of Royal Canin urinary diets per year.
The company has enlisted the support of an independent laboratory to carry out an infrared spectroscopy analysis of the stones, in order to make a quantitative and qualitative assessment of their composition. Royal Canin says that by appreciating the mineral-type in all layers, the best dietary recommendation can be made.
Lee Danks, Royal Canin’s Veterinary Scientific Support Manager, said: "Managing cat and dog urolithiasis can be challenging. This valuable service will improve practices’ diagnostic capacity, enabling a better understanding of a patient’s condition and a much more individualised approach to treatment and long-term prevention."
Royal Canin says there are many complex and interacting contributors to urinary stone formation1. Dietary modifications can influence urine pH, the concentration of minerals within the urine and most critically, urine turn-over through the bladder2. The many interactions between promotors and inhibitors of urolithiasis highlight just how critical a tailored nutritional approach can be to the long-term health of urinary patients.
References
The Veterinary Medicines Directorate (VMD) has given VetSurgeon the data on which these stories were based.
In the 3.5 years since the vaccine was authorised, the incidence of suspected adverse animal reactions has been 0.064%. In other words, for every 10,000 doses sold, the VMD has received reports of 6 suspected adverse reactions. This incidence is considered 'rare', according to the following convention:
The VMD reports that amongst the 40+ authorised dog vaccines in the UK, the incidence of suspected adverse reactions ranges from 0.002% (classified 'very rare') to 0.3% (classified 'uncommon')
However, the VMD is at pains to stress that suspected adverse reaction reports should not be used to compare the relative safety of products. They are, after all, only 'suspected' adverse reactions. The reliability of suspected adverse reaction reports is further complicated by the fact that vaccination against leptospirosis rarely occurs in isolation, making it very difficult to interpret which adverse reactions are attributable to Leptospira vaccines.
Many vaccines providing protection against leptospirosis also contain components for prevention of other diseases, such as distemper, parainfluenza and parvovirus. In addition, many dogs are vaccinated concurrently against other diseases, such as kennel cough and/or rabies, and other products (e.g. flea and worm treatments) may be administered at the same visit. Therefore the clinical signs observed may be related to any of the products used or they may be unrelated.
The VMD says the majority of the most commonly reported suspected adverse reactions to Nobivac L4 are linked to allergic type reactions which are well-recognised potential side effects of any vaccine, and are presented on the product literature.
As to the newspaper claim that: "The World Small Animal Veterinary Association (WSAVA) is urging owners not to use Nobivac L4 vaccine on puppies under 12 weeks old.", the WSAVA denied this in the strongest possible terms, saying: "This statement is blatantly untrue. The WSAVA would never ‘urge owners’ and would never make recommendations about individual named commercial products."
In a statement issued in response to the newspaper story, MSD said: "Nothing is more important to MSD Animal Health than the safety and efficacy of our products, and the health and well-being of animals.
"Nobivac L4 was launched in 2013 across Europe to prevent dogs from contracting Leptospirosis which is a serious zoonotic disease. It is one of the most widely used vaccines for dogs with several million doses being used annually to successfully prevent infection in dogs."
"As a responsible animal health company, we take every adverse reaction report seriously and investigate thoroughly. Whenever possible, we work with the pet owner and attending veterinary surgeon to assemble as much clinical information as we can to help determine the cause of a pet’s health issue, and whether or not the product may have been involved .
"We report findings to governing regulatory agencies around the world (based on a country’s respective laws and policies), so that they can make a fully informed, scientific assessment about the safety of the product. We do this so that accurate safety and efficacy information is available for veterinary surgeons prescribing our products."
In a parting shot, the WSAVA said: "The WSAVA guidelines are publicly available on-line and this journalist has clearly not undertaken adequate research before publishing this article."
See: www.wsava.org/educational/vaccination-guidelines-group
Currently used by more than 200 practices and 50 universities around the world, the Equinosis Q is a diagnostic tool that can further aid the subjective lameness evaluation on all types of horses and ponies examined in the field or in hospital settings.
Christina Frigast, MRCVS, Eickemeyer Product Development Manager said: "The inertial sensors sample 20x faster than the human eye making the Equinosis Q a valuable tool to the veterinarian in the evaluation of subtle and multiple limb lameness.
"It does not interfere with the routine lameness examination as trot up on straight line, lunging and ridden evaluations can be performed on both hard and soft surfaces.
"Data is wirelessly streamed to a tablet PC and compiled into a reader-friendly report displaying the timing and severity of lameness. The effectiveness of diagnostic blocks can also be assessed with the Equinosis Q, providing the veterinarian with a percentage of improvement. In addition, comparison reports can be used to monitor rehabilitation progress."
Contact Eickemeyer to book a free demo, or for further information, visit: https://www.eickemeyer.co.uk/Diagnostics-and-Education/Anatomy-Models/Lameness-Locator-vet.html?listtype=search&searchparam=lameness
watch?v=MS6UXQSq6q0
The kit contains a guide to effective ear cleaning, an illustrated step-by-step instruction guide on how to administer the Canaural, and a diary and consultation pack so owners can engage with the diagnosis and treatment of their pet’s ear infection.
The Healthy Ears Combi Kit comes in a resealable wipe-clean bag and is available free of charge from veterinary wholesalers.
Dechra Brand Manager Claire Morgan said: "The new kit will give owners more confidence in the important role that they play in their pet’s ear health and encourage them to engage in the treatment plan, thereby supporting veterinary professionals in the cycle of care.
"As well as serving as practical storage for the products, it acts as a reminder to dispense CleanAural as well as Canaural, as the self-cleaning mechanism of the animal’s ears is often compromised by infection.
She added: "CleanAural does not compromise the antimicrobial activity of Canaural1 so they are perfect partners for maintaining healthy ears."
Free Healthy Ears Combi Kit can be ordered via your veterinary wholesaler.
Reference
Drawing attention to the symptoms of allergic skin disease that owners should look out for during the warmer months, the leaflet, poster and notice board materials discuss some of the substances that dogs can be allergic to, how to manage skin allergies and what to look for in an itch prevention plan.
The materials have been produced to support Apoquel, the oral therapy for the treatment of canine pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis. They feature two dogs – Eric and Daisy – whose lives have been changed by the product.
For more information, contact your Zoetis account manager.
Bovalto Respi vaccines contain a newly developed combination of viral and bacterial antigens. Merial says the recent vaccine isolates effectively target current European-circulating Bovine Respiratory Disease (BRD) strains. Bovalto antigens are also proven by challenge, including at six months post-vaccination to confirm long-lasting protection.
Henry Berger, Global Head of the Ruminant and Equine Business Unit at Merial, said: "Merial is committed to understanding the needs of cattle producers and delivering unique, targeted solutions. Merial is dedicated to expanding its portfolio of parasiticides, vaccines and other disease prevention solutions, with high-value products like Bovalto Respi, to improve productivity, and keep herds healthy."
Merial highlights that BRD is complex to manage and each year affects an estimated 1.9 million animals1, costing the UK cattle industry around £60 million2. In Ireland BRD is responsible for 30% of deaths in stock under one-year old3.
At a Merial symposium at WBC 2016, Prof. Sandro Cavirani, Director of the Department of Animal Health at the University of Parma, Italy highlighted the importance of successful BRD control programmes in calves to optimise herd immunity and productivity, including early, repeated and targeted BRD vaccination.
Bovalto Respi 3 contains strains of Parainfluenza Virus 3, Bovine Respiratory Syncytial Virus, and Mannheimia haemolytica serotype A1. The combination in Bovalto Respi 4 combines the three pathogens in Bovalto Respi 3, with the added strain of Bovine Viral Diarrhoea Virus (BVDV).
The 3D dental model, which was produced with the help of veterinary dentist John Robinson, demonstrates the recommended method for sectioning and extracting teeth in cats and dogs.
An accurate representation of the animal’s mouth, the teeth are pre-sectioned, indicating how tooth crowns should be divided and where to cut the crown to achieve single root pieces.
Royal Canin's Veterinary Marketing Manager, Marianne Lomberg, said: "We are delighted to offer this new learning tool. These high quality and accurate models will be a valuable addition to the education resources available to veterinary schools and professionals – ultimately helping contribute to a higher standard of dental care available to cats and dogs."
Orders of £300 will receive one free model, orders of £500 will receive two free models.
For more information, contact your Royal Canin Veterinary Business Manager or visit www.vetportal.royalcanin.co.uk.
Amanda Melvin, Senior Product Manager, said: "We’re very excited about this approval as it will allow us to build on the success of our Bravecto chewable tablets for dogs and provide veterinarians and cat owners with another tool in the fight against ticks and fleas. Being able to offer a full 12 week protection means convenience for cat owners and improved compliance rates for veterinarians, so everyone benefits."
Bravecto is applied topically using the new "Twist’n’Use" pipette design which means the cap doesn’t need to be removed.
Full product details are described in the summary of product characteristics (SPC).
For more information, contact your MSD Animal Health representative.
It is hoped the findings, which were unveiled at the House of Commons yesterday, will enable the welfare priorities of the UK’s 800,000 horses to be addressed.
This is the first time welfare organisations, breeders, the equine industry and the veterinary profession have come together to agree on a strategy to best improve the welfare of horses in the UK.
The equine welfare study found the welfare needs of many horses are not currently being met and the report has highlighted four welfare priorities.
Dr Siobhan Mullan, Research Fellow in Animal Welfare Science, Ethics and Law at the University of Bristol and one of the report’s authors, said: "Bringing together the views of people associated with horses in England and Wales has provided an overview of horse welfare, from the day-to-day concerns of equine caregivers to identifying four priority challenges to equine welfare.
"This research has also identified how equine welfare can be improved, by addressing both the priority challenges, and a wider set of industry and horse-based needs."
Roly Owers, World Horse Welfare Chief Executive, added: "This research report provides a vital insight to the UK’s equine sector, mapping out the welfare landscape from a wide range of sector experts and stakeholders.
"In order for World Horse Welfare and others to most effectively address the welfare challenges facing UK equines, we need to better understand today’s welfare priorities and this research will provide a valuable guide to help in driving the focus of our educational initiatives and resources over the next few years.”
The priority welfare challenges and solutions outlined in the report are:
Unresolved stress/pain behaviourProblems associated with unresolved stress/pain behaviour affect large numbers of horses, often for long durations with variable severity of suffering caused to individual horses.
More academic research is needed to fully understand the links between behaviour, stress and pain, and objective measures of stress and pain in horses should be developed. Vets, riding instructors, the Pony Club, riding clubs and the equine press have a role in educating horse caregivers about signs of stress and pain and the appropriate responses. Academics and experts also have a role in tackling this issue through evaluating the effectiveness of intervention programmes.
Inappropriate nutritionOverfeeding and obesity are the main welfare problems associated with nutrition and affect large numbers of horses, often for a long time with varying severity of suffering.
Vets have a key role in tackling the problems associated with inappropriate nutrition. A consistent approach by all vets is needed, to prevent horse owners choosing vets that don’t challenge owners about their horses’ nutrition. Feed companies can also play an important role in tackling this issue, although many feed companies already offer appropriate nutrition for a range of horses and exercise situations. Better owner education, based on existing good research, would ensure the right nutritional choices are made for individual horses.
Inappropriate stabling /turnoutWelfare of horses is compromised when the amount of time spent at pasture/stabled does not meet their individual needs, when they are kept in social isolation or when they are exposed to unsuitable grazing conditions. Welfare problems associated with incorrect stabling/turnout affect large numbers of horses for a long time with variable levels of suffering.
Although all horse owners make choices relating to the amount and type of stabling and turnout experienced by their horses, livery yard owners could play a role in addressing this issue. For example, by encouraging different approaches to management, including group housing and the use of all-weather turnout facilities. Strengthening legislation is another possible way for improvement but a ‘one size fits all’ approach would be inappropriate. For example, for some horses, turn out to pasture may not always be suitable.
Delayed deathHorses may be kept alive inappropriately resulting in firstly, prolonging welfare problems, such as continued suffering of a horse in pain. This affects relatively large numbers of horses, for short periods of time with the severity of suffering often being severe. Secondly, an increased risk of suffering, for example where horses are unwanted by their owners, become low value and subsequently aren’t cared for well.
One way for improvement could be by putting pressure on the EU to make changes to the passport regulations. In particular, legislation changes that would enable horses who had received medications, including Phenylbutazone, to be slaughtered to enter the human food chain after a six month withdrawal period. In addition, challenging negative attitudes of horse owners towards timely euthanasia is important.
The research, undertaken over a four year period, was to understand the welfare status of horses in England and Wales, identify priority welfare issues and explore horse owner and industry experts’ perceptions of these issues.
Stakeholders from across the equine industry contributed to the research: from vets to farriers and welfare charities to governing body representatives, participants represented a wide-reaching cross section of horse care roles and responsibilities.
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
The new 10ml (10-dose) and 100ml (100-dose) packs of Ingelvac PRRS EU are available now, and will complement the existing 50ml (50-dose) packs.
Callum Blair MRCVS, Swine Brand Manager at Boehringer Ingelheim, said: "Nobody likes to end up with part used bottles of any vaccine that then have to be discarded. The addition of Ingelvac PRRS EU 10-dose and 100-dose packs will provide choice for different sized units and help reduce wasted doses."
For more information, visit www.prrs.com.
VetSurgeon Editor Arlo Guthrie said: “The original setup, which reorders a list of available positions by distance from a location, works very well when you know where you want to work.
"The new VetSurgeon Jobs Map, on the other hand, is ideal for when you’re not sure where exactly you want to work, and just want to know what’s out there.
"We’ve also added a 'World Jobs Map' so that there’s a quick and easy way to see any jobs outside the UK, such as those currently advertised in Bahrain, South Africa and Ireland."
The VetSurgeon Jobs Map is the latest in a string of new features added since a small charge was introduced for advertising jobs in May, including Find our jobs on VetSurgeon, Share & Reward and the VetSurgeon Locums Map. The same features have also been added over on VetNurse Jobs, too.
Arlo said: "Now that we charge for advertising on VetSurgeon Jobs, I’m interested in only one thing, which is offering both job seekers and recruiters the best service available anywhere."
The Association says that the qualification is intended to give vets the chance to conduct clinical research relating to their work – in particular vets working in general practice.
The qualification, validated by Nottingham Trent University, is aimed at people who already have any accredited Postgraduate Certificate (60 credits at Level 7) relevant to some aspect of veterinary medicine or surgery.
The programme is based on a further 1,200 study hours and could be flexibly achieved in two years of part-time study or up to five years, depending on the project type and an individual’s availability.
Frances Barr, BSAVA Academic Director, has developed the most extensive CPD programme in the 60-year history of the organisation. She said: "It’s a really significant addition to the BSAVA CPD programme and another step supporting lifelong learning, which we hope will have a very positive impact on the profession."
"Anyone who has an interest in clinical research – such as evaluating risk factors for a particular disease or factors that might influence an outcome – will find this an ideal way to satisfy their enquiring mind.
"If they have the motivation to keep developing a deeper understanding, we can provide encouragement and support for how to answer those clinical questions."
The Masters programme starts with online study into the principles of clinical research, which students will then apply to their own research project.
Students will be allocated a ‘matched’ supervisor who will provide project advice and guidance, plus the BSAVA team will be on hand to ensure ongoing support and encouragement.
The programme starts in January 2017 and applications open this October.
Frances added: "It can sometimes be quite difficult to get going in research when you don’t know how to do it, so having taken the first step in a supported environment we hope many will go on to do extend their clinical research ambitions.
"BSAVA’s mission is to support vets at every stage of their careers. There are often limited opportunities for practitioners to conduct clinical research, so this is a qualification that enables vets to do just that."
For more information, please contact the BSAVA Education team at masters@bsava.com
At the start of June, the British Veterinary Association (BVA), British Cattle Veterinary Association (BCVA), Goat Veterinary Society (GVS), and Sheep Veterinary Society (SVS) welcomed the announcement that bluetongue (BTV-8) vaccine would be available by mid-July to support farmers and smallholders in managing the risk of a bluetongue outbreak predicted to reach mainland UK by late summer.
Since the Defra risk assessment indicates a high risk by late summer of a BTV incursion from France, veterinary associations have been involved in discussions with government, farmers’ representatives and manufacturers to ensure vaccine is available to meet potential demand particularly in the south of England where risk is highest. The situation remains under constant review by Defra as the disease develops and the weather warms up, promoting midge activity.
Pharmaceutical companies MSD and Zoetis announced that batches of vaccine would be available from mid-July, which Defra has just confirmed.
Vets across the UK are also contributing to the Joint campaign Against Bluetongue (JAB), helping to make farmers aware of the risk, clinical signs and what action to take, through speaking at local JAB information events and displaying posters and leaflets in practices.
While welcoming the announcement of vaccine availability in June, veterinary organisations also sought clarification about the cost and the amount of vaccine likely to be available in July and thereafter. This information is now available.
BVA President Sean Wensley said: "We welcome the announcement that vaccine will be available in time to meet potential demand. This disease seriously affects animal health and welfare as well as the productivity of livestock, and vaccination is the key control."
Photo by Fourrure (http://www.boulesdefourrure.fr) [CC BY-SA 2.0], via Wikimedia Commons
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
The event will again be held at Loseley Park in Surrey, on Friday 9th and Saturday 10th June 2017.
New for 2017, VET Festival will be introducing an Internal Medicine stream which will cover the themes of Emergency & Critical Care, Endocrinology, Cardiology, Reproduction, Respiratory and Small Furries.
There will also be a new stream dedicated to Rehabilitation, which will join Orthopaedics, Neurology, Oncology and Soft Tissue, Nursing and Management and Motivation. Delegates are free to join any lecture at any stream and attendance to VET Festival will contribute towards their CPD.
Professor Noel Fitzpatrick, who conceived VET Festival, said "The aim of the VET Festival is very simple – to provide the best veterinary education in the world so as to ensure the best standard of care for our animal friends, delivered in the most exciting environment on Planet Earth where all of the finances return to helping the animals.
"I believe that people who love companion animals will be aware of our need to receive the very highest level CPD and that both delegates and exhibitors deserve real value for money. I’m determined that the festival is firmly focussed on the greater good of the welfare of animals entrusted to our care – and on maintaining the fire in our bellies that we first had when we signed up for this vocation.
"My dream is to create a Glastonbury for Veterinary Medicine in my lifetime and that VET Festival will be the most interesting, innovative, exciting, dynamic, informative, career-enhancing and personally fulfilling veterinary CPD in the world.
"I have absolutely zero doubt that within five years VET Festival will be a key event in the veterinary education calendar for one simple reason, and that is we reinject the happiness into the reason why we started this journey in the first place. We want delegates to feel love for their profession and respect for everything that they do.
"Most importantly I want people to feel fulfilled because every single day that they go to work as a veterinary professional, they don’t really do it just for monetary gain. They do it because they want to make a difference. When the delegates leave VET Festival, I want them to know that they have made that difference."
Brian Topper, Managing Director of Centaur Services, one of the official partners of VET Festival 2016, said: "I think VET Festival is awesome. It’s different than anything we have done in the UK and US veterinary industry. It’s very timely as people are getting tired of the traditional route to education. This is a great opportunity and we are very happy to participate. I have been in the industry for 20 years and I have seen nothing like VET Festival. Wherever VET Festival goes, we will be here!"
Consistent with previous surveys, lameness was shown to be more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross carries out NEHS in May each year in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by Dodson & Horrell and Zoetis and supported by the UK’s leading equestrian organisations and charities.
This year saw a 14% increase in participation compared to 2015, with survey records returned for almost 16,751 horses, ponies, donkeys and mules and 5635 people taking part. Most horses were kept in livery or a private yard and used for leisure and hacking.
Lameness has been consistently seen as the most common syndrome affecting horses in the NEHS results year on year. In the latest survey a total of 32.9% (24.4% in 2015) of horses and ponies with health problems were recorded as lame. Overall, as in previous years, lameness in the limb was more common than lameness caused by problems in the foot.
A breakdown of the types of lameness revealed that 47.4% were recorded as suffering from proximal limb lameness, 31.9% from causes of foot lameness other than laminitis and 20.7% from laminitis. Degenerative joint disease (including foot and proximal limb) was the most frequently reported single cause of lameness (41.2% of all lameness) and the most frequently reported joint affected by DJD was the hock (15.3% of all lameness).
Reports of foot lameness (excluding laminitis) more than doubled this year at 10.5% (4.5% in 2015) of all syndromes reported with pus in the foot being the most frequently recorded problem. This could possibly be attributed to the persistent wet weather during and prior to the survey, which can increase susceptibility to the condition.
Josh Slater from the Royal Veterinary College, who is a member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: "The data gleaned from the survey remains consistent year on year, confirming the reliability of our findings for benchmarking, referencing and research. This year’s increase in overall lameness may be in part attributed to the higher incidence of pus in the foot but may also be because owners are becoming more aware of lameness issues. Ongoing research on lameness has generated significant media coverage over the past year, helping to raise understanding of the importance of accurate diagnosis and treatment both from welfare and performance perspectives."
The six most notable disease syndromes identified in the 2016 National Equine Health Survey are:
Gemma Taylor, Education Officer at Blue Cross said: "The significant increase in participation again this year shows that owners and keepers of horses are really getting behind the survey and recognising its importance in safeguarding the future health and of the UK’s horses. Over the past year NEHS data has been referred to in leading equestrian and veterinary media, showing its credibility as a valuable benchmarking reference."
The 2016 NEHS survey results are now available. To download a copy visit http://www.bluecross.org.uk/nehs2016results and to register for next year’s survey please visit www.bluecross.org.uk/nehs
As part of its continued support of the 2016 regional events organised by VPMA and SPVS, in partnership with Zoetis, the company is sponsoring the ‘Focus on the Practice Team’ course on Thursday 13 October at Chesford Grange, Warwickshire. Four veterinary professionals will be selected at random to win a place worth £210.
Royal Canin says the day will bring together some of the best experts in leadership, management, employment law and staff training to ensure that practices are ahead of the game when it comes to trained, happy and well managed staff.
The first half of the day will concentrate on the impact front of house employees can have on client communication, whilst the second half will cover HR issues. Guest speakers include Brian Faulkner from The Colourful Consultancy, Nick Steele from Zoetis, Veterinary Mentor, Carolyne Crowe, and Alison Lambert from Onswitch.
To have a go at winning a free place, send an email with your name, job title, the name of your veterinary practice and the reason why you would like to attend to royalcaninvet.gbr@royalcanin.com by Friday 30 September. The company will then select four applicants at random and will inform the winners via email by Friday 7 October.
Places on the course can also be booked by calling 01453 872731 or by visiting www.spvs-vpma-events.co.uk. Focus days cost £175 plus VAT for non-members and £125 plus VAT for VPMA and SPVS members (group/ bulk booking discounts are also available). The cost includes lunch and refreshments.
TVM, which has a wide range of products in ophthalmology, neurology, geriatrics, gastroenterology, anti-poison management and health and wellness, says that the acquisition is designed to boost the company's international scope, building market share and expanding its leadership in the fields of ophthalmology and neurology beyond France.
The acquisition will also strengthen TVM’s position in the area of animal anti-poison treatment as Forum Animal Health already supplies a canine emetic which it has been marketing in the UK for three years with an awareness campaign about the dangers of toxic products to dogs. This, the company says, has contributed to a significant increase in early interventions by veterinary surgeons in cases of poisoning. A similar campaign is currently being led in France by the TVM laboratory.
To accompany the change, Forum Animal Health is adopting a new visual identity, shown above right.
Almost all rabies cases are as a result of being bitten by an infected dog, with around half of all dog bites and rabies deaths occurring in children under 15 years of age. Rabies, which is preventable, is categorised as one of the 17 Neglected Tropical Diseases by the World Health Organization (WHO).
The End Rabies Now campaign aims to significantly raise the profile of rabies as a global neglected tropical disease with policy makers and journalists, explaining what is being done to control and eliminate the disease. The campaign is led by Global Alliance for Rabies Control (GARC), and has three key messages:
Ahead of the tenth World Rabies Day, BVA has also recognised vet Professor Sarah Cleaveland OBE for her work in rabies control by awarding her the Chiron Award, one of the Association’s most prestigious awards for outstanding contributions to veterinary science.
Sarah said: "Awards like this are recognition of the contributions not only of one person, but the work of many. We are deeply committed to continuing our efforts towards the global elimination of canine rabies and tackling other zoonotic diseases that affect the health and livelihoods of many of the poorest people in the world."
The End Rabies Now campaign is based around the strong scientific evidence that vaccinating dogs is fundamental to disrupting the cycle of rabies transmission to humans. The target of 2030 was chosen because one of the UN’s sustainable development goals, launched in September 2015, includes the ambition to end by 2030 neglected tropical diseases such as rabies.
With 120 countries still affected by canine rabies, the End Rabies Now campaign advocates that collaborative cross-sector efforts are needed to end zoonotic diseases such as rabies: rabies elimination plans must include human and animal government agencies, veterinary and human health professionals, educators, scientists and community groups.
BVA President Gudrun Ravetz said: "The work being done worldwide by vets, human health professionals and others to combat this horrific disease that senselessly kills thousands each year is of the utmost importance and BVA is proud to support the End Rabies Now campaign and help get those key messages out to policy makers and governments worldwide – every rabies death is entirely preventable and we can end rabies by 2030 through vaccinating dogs."
Amflee Combo, a POM, is being launched by a newcomer to the UK market, a Slovenian company called Krka (pronounced kirka). The company says it plans to introduce a vast range of small and production animal products onto the UK market in the next few years.
Killian Gaffney, Head of sales and marketing at Krka, says the company intends to support UK veterinary surgeons by offering high quality products and by building business relationships that will help protect veterinary incomes, at the same time as offering good value to their customers.
Killian said: "Amflee Combo has some unique features that we believe will set it apart from the competition. We know the combination of the two active ingredients in Amflee Combo is very effective for the treatment of fleas, ticks and biting lice and as part of a treatment strategy for flea allergy dermatitis in dogs and cats. S-methoprene is also effective against flea eggs and larvae in the environment.
"However, these ingredients can be susceptible to degradation when subjected to light and moisture, which is why each Amflee Combo pipette comes in its own special foil wrapper. The pipettes have also been designed for convenience of use, since we know that only 22% of owners apply spot-ons correctly1."
A range of product and client literature to support the use of Amflee Combo is available by calling 01753 722 150.
Amflee Combo is available in a variety of packs for cats and different sized dogs, containing either three or six pipettes. The recommended treatment is one pipette every four weeks.
Further information about Amflee Combo or Krka is available at www.krka.co.uk
1 El veterinario ante el cambio climatico Argos 107, 2010.
Specifically, the review is of The Non-Commercial Movement of Pet Animals Order 2011 as amended by the Non-Commercial Movement of Pet Animals (Amendment) Order 2014.
The consultation is seeking opinions on whether:
The consultation is not about potential changes to the legalisation following Brexit although evidence collected as part of this review may be relevant to future discussions.
The BSAVA says it is aware that the changes to the Pet Travel Scheme, introduced in January 2012 and December 2014, have significantly increased the number of animals, particularly puppies, entering the UK including those for sale which should not be coming in under the Pet Travel Scheme.
It says it also knows that a significant number of veterinary practices have been presented with animals that do not fully comply with the requirements of the Pet Travel Scheme and that contacting the appropriate department in the Local Authority is not always easy.
The Association is therefore encouraging members of the profession to feed into this consultation and encourage any clients who have experience of travelling to and from Europe with their pets to do so as well.
The BSAVA says it will be submitting a response itself, and if anyone would rather send their comments via the BSAVA, you should email Sally Everitt (Head of Scientific Policy) s.everitt@bsava.com by 20th October.
During the four-day hearing, the Committee heard evidence in respect of three separate heads of charge brought against Mr Shah following a castration operation conducted on Shadow, a six-year old Newfoundland dog, which took place on 20 June 2014.
The three charges were as follows:
There was no complaint made as to the undertaking of the operation itself, and the Committee followed the advice from the Legal Assessor that each charge should be considered separately. When making its decision, the Committee did not take into account the fact that Shadow had died as it is impossible to say whether he would have survived had Mr Shah acted differently.
The Committee found each of the allegations against Mr Shah proved. In respect of the first charge the Committee heard from two expert witnesses, Professor Williams and Mr Plumley, who agreed that the decision to discharge Shadow at about 6pm on 20 June 2014, given his condition, was inappropriate.
The Committee considers that discharging Shadow at that time into the care of the owner given his state on discharge, was grossly negligent and a serious error of judgement. It therefore found Mr Shah to be guilty of the first charge.
The Committee then considered that, after being alerted to Shadow’s continued lack of progress by the telephone call from Gemma Ballantyne between 30 and 45 minutes after discharge, Mr Shah exacerbated the situation by the inadequacy of his response in dealing with the concerns raised which, in the Committee’s view, represented a continuation of his previous poor judgement.
The Committee considered that Mr Shah was under a duty of care to advise Gemma Ballantyne to seek urgent veterinary attention for Shadow and by his own admission he failed to do so, and he was therefore found guilty of the second charge.
During that telephone call Mr Shah also gave no further details about the out-of-hours care available to Gemma Ballantyne other than to inform her that there would be an additional cost.
He did not seek confirmation that any such information been supplied by his colleague, Emma Martin (who at the relevant time was a student nurse), however, and at no time did he see Gemma Ballantyne in possession of the discharge sheet. The Committee therefore found Mr Shah guilty of this final head of charge.
The Committee did accept that there was no element of dishonesty, nor was there an aim of financial gain in the case. The Committee also considered that Mr Shah was acting in good faith at all times. It also accepted that Mr Shah was entitled to assume that normal practice had been followed and that a previously compiled discharge sheet, containing the number of the out-of-hours provider, had been supplied to Miss Ballantyne.
Ian Green, chairing the Committee and speaking on its behalf, said: "Balancing all of the factors as the Committee must, it is clear that on this occasion Mr Shah’s conduct fell far short of that which is expected and it therefore finds he conducted himself disgracefully in a professional respect."
Mr Green added: "In imposing the sanction of a reprimand, the Committee urges Mr Shah in the strongest possible terms to ensure that his future conduct by way of training and support systems within his practice are such as to avoid any possibility of a future incident such as this occurring in order to ensure animal welfare and public confidence in the veterinary profession. The Committee notes that in her evidence, Emma Martin said that the working practices at the surgery have been changed and the Committee expects that all animals kept in the care of Mr Shah are fully monitored, examined and assessed in relation to their condition before being discharged."